Pfizer
NEWS
Voyager Therapeutics entered a deal with Pfizer that allows Pfizer to exercise options to license novel capsids created by Voyager’s RNA-driven TRACER screening technology.
With the planned departure from its 561,652-square-foot RTP campus, GSK will reduce its geographical footprint, but not its staff.
There is — still — plenty of news about COVID-19 and new drugs, therapies and FDA applications. Here’s a look.
Data from the Phase II CYPRESS study presented at the virtual IDWeek (Infectious Disease Week) 2021 showed that the vaccine candidate provided a robust response against the infection.
Johnson & Johnson is expected to ask the U.S. Food and Drug Administration to authorize a booster for its one-shot COVID-19 vaccine this week.
First COVID-19, now cancer. BioNTech made history when its COVID-19 mRNA vaccine with partner Pfizer became the first ever approved.
The Pfizer-BioNTech booster shot is now authorized for people over 18 and 65 who are immunocompromised, at high risk due to their work or living situation and front-line healthcare workers.
Pfizer reported three cases of muscle weakness, two of which involved inflammation of the heart (myocarditis).
Biomolecular condensates could hold the key to unlocking a number of neurological diseases that have baffled researchers the longest.
JOBS
IN THE PRESS